Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company developing a proprietary RaniPill delivery platform that can enable the oral administration of traditionally injectable biologics. This platform has been validated in multiple Phase 1 studies, demonstrating high bioavailability, and the potential for once-weekly oral dosing. The company has also secured partnerships with major biopharmaceutical companies and is advancing its pipeline of oral therapeutics. With an expected positive readout in the Phase 1b human PD study for RT-114, the company is well-positioned to validate its platform and attract potential partners, making it an attractive investment opportunity.

Bears say

Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company with a unique platform technology, RaniPill, that offers a convenient alternative to painful injections for biologics. However, the company's extensive preclinical and in-human dataset may not be enough to assure efficacy and safety, as transit variability and chronic, repeat-dose performance remain relatively unvalidated. Additionally, the company's valuation is driven by its key franchises, which have varying probabilities of success, and any management turnover could negatively impact the company's progress and performance.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.